User profiles for "author:D. M. Harper"

Diane M Harper

University of Michigan, Deputy Editor, eLife
Verified email at med.umich.edu
Cited by 44355

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

D Saslow, PE Castle, JT Cox, DD Davey… - CA: a cancer journal …, 2007 - Wiley Online Library
Abstract The American Cancer Society (ACS) has developed guidelines for the use of the
prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical …

[HTML][HTML] HPV vaccines–a review of the first decade

DM Harper, LR DeMars - Gynecologic oncology, 2017 - Elsevier
Abstract Pre-adolescent girls (9–15 years) have the option of receiving a two dose HPV
vaccine series at either a six month or one year interval to provide protection from HPV 16 …

[PDF][PDF] Human papillomavirus and HPV vaccines: a review

FT Cutts, S Franceschi, S Goldie… - Bulletin of the World …, 2007 - SciELO Public Health
Cervical cancer, the most common cancer affecting women in developing countries, is
caused by persistent infection with" high-risk" genotypes of human papillomaviruses (HPV) …

[HTML][HTML] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

SM Garland, M Hernandez-Avila… - … England Journal of …, 2007 - Mass Medical Soc
Background A phase 3 trial was conducted to evaluate the efficacy of a prophylactic
quadrivalent vaccine in preventing anogenital diseases associated with human …

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

DM Harper, EL Franco, C Wheeler, DG Ferris… - The lancet, 2004 - thelancet.com
Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo …

LL Villa, RLR Costa, CA Petta, RP Andrade… - The lancet …, 2005 - thelancet.com
Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

Screening for colorectal cancer: US Preventive Services Task Force recommendation statement

K Bibbins-Domingo, DC Grossman, SJ Curry… - Jama, 2016 - jamanetwork.com
Importance Colorectal cancer is the second leading cause of cancer death in the United
States. In 2016, an estimated 134 000 persons will be diagnosed with the disease, and …

[HTML][HTML] Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised …

DM Harper, EL Franco, CM Wheeler, AB Moscicki… - The Lancet, 2006 - thelancet.com
Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim …

J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón… - The Lancet, 2007 - thelancet.com
Background The aim of this interim analysis of a large, international phase III study was to
assess the efficacy of an AS04 adjuvanted L1 virus-like-particle prophylactic candidate …

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …

EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …